D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 77 Citations 41,562 337 World Ranking 11246 National Ranking 336

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Gene

Francois Guilhot spends much of his time researching Internal medicine, Imatinib, Myeloid leukemia, Imatinib mesylate and Surgery. As part of his studies on Internal medicine, Francois Guilhot often connects relevant subjects like Oncology. His Oncology research includes elements of Hematology, Transplantation and Chronic phase chronic myelogenous leukemia.

His study in Imatinib is interdisciplinary in nature, drawing from both Cytarabine, Chronic myelogenous leukemia and Tyrosine-kinase inhibitor. His Myeloid leukemia research incorporates elements of Gastroenterology, Hematologic Response and Minimal residual disease. His Imatinib mesylate study frequently links to adjacent areas such as Myeloid.

His most cited work include:

  • Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial (1084 citations)
  • Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet (1080 citations)
  • Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet (1069 citations)

What are the main themes of his work throughout his whole career to date?

His primary scientific interests are in Internal medicine, Imatinib, Imatinib mesylate, Myeloid leukemia and Oncology. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Surgery. His biological study deals with issues like Chronic myelogenous leukemia, which deal with fields such as Philadelphia chromosome and Chronic phase chronic myelogenous leukemia.

His research investigates the connection between Imatinib mesylate and topics such as Cytarabine that intersect with issues in Alpha interferon. His Myeloid leukemia research is multidisciplinary, incorporating perspectives in Tyrosine kinase, Leukemia and Tyrosine-kinase inhibitor. The Dasatinib study combines topics in areas such as Nilotinib and Phases of clinical research.

He most often published in these fields:

  • Internal medicine (63.13%)
  • Imatinib (44.37%)
  • Imatinib mesylate (34.06%)

What were the highlights of his more recent work (between 2015-2021)?

  • Internal medicine (63.13%)
  • Myeloid leukemia (33.44%)
  • Oncology (23.12%)

In recent papers he was focusing on the following fields of study:

The scientist’s investigation covers issues in Internal medicine, Myeloid leukemia, Oncology, Ponatinib and Imatinib. Internal medicine is represented through his Dasatinib, Adverse effect, Nilotinib, Discontinuation and Imatinib mesylate research. His studies deal with areas such as Tyrosine kinase, Leukemia, Minimal residual disease, Tyrosine-kinase inhibitor and Pharmacology as well as Myeloid leukemia.

His study in Tyrosine-kinase inhibitor is interdisciplinary in nature, drawing from both Chronic myelogenous leukemia and Immunology. His Oncology study combines topics in areas such as Quality of life and Transplantation. His work carried out in the field of Imatinib brings together such families of science as Gastroenterology and Phases of clinical research.

Between 2015 and 2021, his most popular works were:

  • Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia (206 citations)
  • Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial (203 citations)
  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (160 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

His main research concerns Internal medicine, Myeloid leukemia, Imatinib, Adverse effect and Dasatinib. The study incorporates disciplines such as Surgery and Oncology in addition to Internal medicine. Myeloid leukemia is closely attributed to Leukemia in his research.

His research in Imatinib is mostly focused on Imatinib mesylate. His Adverse effect study incorporates themes from Clinical endpoint, Ponatinib and Cumulative incidence. His Tyrosine-kinase inhibitor research integrates issues from Chronic myelogenous leukemia, European LeukemiaNet, Bosutinib and Immunology.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann.
The New England Journal of Medicine (2003)

4164 Citations

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann.
The New England Journal of Medicine (2006)

3961 Citations

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot.
The New England Journal of Medicine (2002)

2532 Citations

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

François-Xavier Mahon;Delphine Réa;Joëlle Guilhot;François Guilhot.
Lancet Oncology (2010)

1818 Citations

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study

Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman.
Blood (2002)

1713 Citations

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus.
Blood (2006)

1700 Citations

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser.
Journal of Clinical Oncology (2009)

1667 Citations

Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

Michel Attal;Jean-Luc Harousseau;Thierry Facon;François Guilhot.
The New England Journal of Medicine (2003)

1414 Citations

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.

A. Hochhaus;S. G. O'Brien;F. Guilhot;B. J. Druker.
Leukemia (2009)

1050 Citations

International randomized study of interferon vs STI571 (IRIS) 8-year follow up : Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib

Michael Deininger;Stephen G O'Brien;François Guilhot;John M Goldman.
Blood (2009)

794 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Francois Guilhot

Jorge E. Cortes

Jorge E. Cortes

Augusta University

Publications: 446

Hagop M. Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Publications: 432

Andreas Hochhaus

Andreas Hochhaus

Friedrich Schiller University Jena

Publications: 253

Michele Baccarani

Michele Baccarani

University of Bologna

Publications: 186

Elias Jabbour

Elias Jabbour

The University of Texas MD Anderson Cancer Center

Publications: 182

Giuseppe Saglio

Giuseppe Saglio

University of Turin

Publications: 174

Michael W. Deininger

Michael W. Deininger

Huntsman Cancer Institute

Publications: 162

Susan O'Brien

Susan O'Brien

University of California, Irvine

Publications: 161

Giovanni Martinelli

Giovanni Martinelli

University of Bologna

Publications: 143

Brian J. Druker

Brian J. Druker

Oregon Health & Science University

Publications: 134

Jane F. Apperley

Jane F. Apperley

Imperial College London

Publications: 126

Moshe Talpaz

Moshe Talpaz

University of Michigan–Ann Arbor

Publications: 117

Guillermo Garcia-Manero

Guillermo Garcia-Manero

The University of Texas MD Anderson Cancer Center

Publications: 114

Jerald P. Radich

Jerald P. Radich

Fred Hutchinson Cancer Research Center

Publications: 113

Farhad Ravandi

Farhad Ravandi

The University of Texas MD Anderson Cancer Center

Publications: 106

Francis J. Giles

Francis J. Giles

National University of Ireland, Galway

Publications: 105

Trending Scientists

Amos Fiat

Amos Fiat

Tel Aviv University

Salem benferhat

Salem benferhat

Artois University

Vivek Agarwal

Vivek Agarwal

Indian Institute of Technology Bombay

Dong Youn Seo

Dong Youn Seo

LG (United States)

Fred H. Kulhawy

Fred H. Kulhawy

Cornell University

Torsten Söderström

Torsten Söderström

Uppsala University

Gilbert C. Walker

Gilbert C. Walker

University of Toronto

Peter Zapol

Peter Zapol

Argonne National Laboratory

Liang Huang

Liang Huang

Huazhong University of Science and Technology

Edouard G. Stanley

Edouard G. Stanley

University of Melbourne

Michael Mendl

Michael Mendl

University of Bristol

Jocelyn K. C. Rose

Jocelyn K. C. Rose

Cornell University

Paul C. Stoy

Paul C. Stoy

University of Wisconsin–Madison

Weihong Li

Weihong Li

Chinese Academy of Sciences

Shankar Aswani

Shankar Aswani

Rhodes University

David S.K. Magnuson

David S.K. Magnuson

University of Louisville

Something went wrong. Please try again later.